entertainment -WSS

entertainment

author：explore 2025-09-27 21:54:22 - browse：661

Among the pharmaceutical companies’ many objections to the Biden administration’s drug pricing program is a set of provisions the industry says will warp how cancer drugs are developed. On Wednesday, AstraZeneca CEO Pascal Soriot proposed a new solution.

“What we were asking — and are asking now — is a very simple fix,” said Soriot at the STAT Future Summit, saying that “the impact on health care costs would be very marginal.”

The problem, executives say, is that companies developing cancer drugs today generally start small and then go big. They seek approval first in a small setting, such as patients who have exhausted all other therapies, where it’s easiest in terms of trial size and length to show a benefit. Then they go into larger settings, such as newly diagnosed patients, where studies take longer but the revenue potential is much higher.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Jerome Adams on the need for new antivirals for Covid
Next article： The surgeon had a dilemma only a Nazi medical text could resolve

focus

WSS

EU regulator recommends expanding Mounjaro approval to obesity

Prior authorization will have to move faster under new Biden rule

Sweden knocks USA out of World Cup in penalty kicks

Trump used to be more articulate. What could explain the change?

Sage considers ways to reduce costs following FDA rejection

Judge in Trump's classified documents case questions use of out

focus

entertainment

leisure time

ChatGPT in medicine: STAT answers readers' burning questions

Humana cuts profit projections as Medicare Advantage costs soar

Supreme Court strikes down use of affirmative action

It was time to plan for my old age. If only I could stop crying

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Tuberculosis patients need more than just free medication

Medicare details structure of new drug price negotiation program

NFL doctors' conflicts of interest could endanger players, report says

The high cost of giving birth even with insurance

Election results set back Medicaid expansion plans

focus

Doctors push to include dialysis machines in emergency stockpile

Doctors are clamoring for more clarity on Paxlovid prescribing

Doctors are clamoring for more clarity on Paxlovid prescribing

Prior authorization will have to move faster under new Biden rule

How CRISPR works, explained in two minutes

AI generated plenty of interest at JPM but not a lot of trust

hotspot

focus

focus

entertainment